Please use this identifier to cite or link to this item:
|Title:||Association of the CYP2C19 *2 allele on the occurrence of in-stent restenosis in patients undergoing coronary stenting|
Xuereb, Robert G.
Azzopardi, Lilian M.
Coronary arteries -- Stenosis -- Malta
Coronary heart disease -- Chemotherapy
|Publisher:||University of Malta. Department of Pharmacy|
|Citation:||Wirth, F., Zahra, G., Xuereb, R. G., Barbara, C., Fenech, A., & Azzopardi, L. M. (2015, June). Association of the CYP2C19 *2 allele on the occurrence of in-stent restenosis in patients undergoing coronary stenting. Poster session presented at the Nordic Social Pharmacy and Health Services Research Conference & The Nordic Networking Group for Clinical Pharmacy, Tartu, Estonia.|
|Abstract:||A poster presentation regarding the association of the CYP2C19 *2 allele on the occurrence of in-stent restenosis in patients undergoing coronary stenting. Background: Proper functioning of the CYP2C19 enzyme is required to convert clopidogrel to its active metabolites to be able to exert its antiplatelet effect. Presence of the CYP2C19 loss-of-function (LoF) *2 variant allele is associated with a decreased response to clopidogrel which may lead to adverse cardiac events post-percutaneous coronary intervention (PCI). Objectives: To genotype patients undergoing PCI for carriage of the CYP2C19 LoF *2 allele and to analyse whether there is an association between presence of the LoF allele and occurrence of in-stent restenosis (ISR) in these patients.|
|Appears in Collections:||Scholarly Works - FacM&SPha|
Files in This Item:
|Association_of_the_CYP2C19 _2_allele_on_the_occurrence_of_in_stent_restenosis_in_patients_undergoing_coronary_stenting_2015.pdf||650.95 kB||Adobe PDF||View/Open|
Items in OAR@UM are protected by copyright, with all rights reserved, unless otherwise indicated.